The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
Open accessAbstract
BACKGROUND Because low grade serous carcinoma of the ovary is relatively chemo resistant disease, this study evaluated Selumetinib (AZD6244), an inhibitor of mitogen-activated protein kinase kinase (MEK-1/2), and explored associations between RAS, and RAF family mutations with clinical outcome. METHODS Women with recurrent low-grade serous ovarian or peritoneal carcinoma were eligible and received Selumetinib at 100 mg. orally b.i.d. until progression or toxicity were enrolled in Gynecologic Oncology protocol 239(NCT00551070). This trial has been completed and we are reporting the results. The primary endpoint of this trial was to examine tumor response rate to Selumetinib. The study used all-treated patients to determine response rate and overall survival. FINDINGS Fifty-two patients were enrolled over two years. Eight patients (15.4%) had complete (1) or partial (7) responses, and 34 (65%) had stable disease. There were no treatment-related deaths. There were three observed grade 4 toxicities and 46 grade 3 toxicities that occurred in more than one patient. Observed grade 4 toxicities were cardiac (1), pain (1), and pulmonary (1). Grade 3 toxicities that occurred included gastrointestinal (13), dermatologic (9), and metabolic (7). CONCLUSIONS Selumetinib is well tolerated, and is active in the treatment of recurrent low-grade serous carcinoma. In exploratory analyses, response to Selumetinib did not appear to be related to RAS/RAF mutational status. The 63% disease control is encouraging and worthy of further evaluation of MEK inhibitors in this population. This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Self-citationMutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
Singer, G., Oldt, R., Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., & Shih, I.-M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.484 · Cited by 854
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., & Lewis, J. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.389 · Cited by 839
Mutch, D. G., Orlando, M., Goss, T., Teneriello, M. G., Gordon, A. N., McMeekin, S. D., Wang, Y., Scribner, D. R., Marciniack, M., Naumann, R. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6735 · Cited by 426
Self-citationSinger, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408
Rose, P. G., Blessing, J. A., Mayer, A. R., & Homesley, H. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.405 · Cited by 386
Gore, M. E., Fryatt, I., Wiltshaw, E., & Dawson, T. (1990) · Gynecologic Oncology · doi:10.1016/0090-8258(90)90174-j · Cited by 381
Cited by
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
Metadata
- Authors
- Farley, J., Brady, W. E., Vathipadiekal, V., Lankes, H. A., Coleman, R., Morgan, M. A., Mannel, R., Yamada, S. D., Mutch, D., Rodgers, W. H., Birrer, M., & Gershenson, D. M.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 14
- Issue
- 2
- Pages
- 134-140
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2091107854
- Cited by
- 413
- References
- 23
- FWCI
- 32.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(12)70572-7
- The paper
- Farley, J., Brady, W. E., Vathipadiekal, V., Lankes, H. A., Coleman, R., Morgan, M. A., Mannel, R., Yamada, S. D., Mutch, D., Rodgers, W. H., Birrer, M., & Gershenson, D. M. (2013). Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(12)70572-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.